<?xml version="1.0" encoding="UTF-8"?>
<p id="Par61">Convalescent plasma treatment has emerged as a promising option for the control of severe COVID-19 in the absence of specific antivirals. It is a strategy of passive immunization based on utilizing the hyperimmune IgG antibodies produced by individuals after recovering from COVID-19 [
 <xref ref-type="bibr" rid="CR150">150</xref>]. In several case series, clinical improvement and reduction in the viral load have been reported [
 <xref ref-type="bibr" rid="CR151">151</xref>â€“
 <xref ref-type="bibr" rid="CR155">155</xref>]. However, there were no matched controls in these studies. Thus, the ongoing clinical trials will probably provide a higher level of evidence and data about the efficacy and safety of convalescent plasma therapy in COVID-19. We should also be cautious considering the potential severe reactions associated with convalescent plasma use such as anaphylactic reactions or transfusion-related acute lung injury [
 <xref ref-type="bibr" rid="CR150">150</xref>].
</p>
